Clinical Trial Details


Research Study Summary

Advanced Ovarian Cancer


To investigate the efficacy and safety of BIBF 1120 plus chemotherapy as compared to placebo plus chemotherapy in patients with advanced ovarian cancer

Patient Inclusion Criteria:

  • Patients with histologically proven epithelial ovarian cancer, fallopian tube or primary peritoneal cancer of advanced stage, 18 + years of age, life expectancy of at least 6 months

Patient Exclusion Criteria:

  • histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum, clinically relevant non-healing would, ulcer or bone fracture, clinical symptoms of brain metastases

To Learn more

CW ID: 163103
Date Last Changed: July 24, 2013

Clinical Trial Snapshot

18 and up
Overall Status
Facility Type


Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.